BACKGROUND: The exact form of the association between systolic blood pressure (SBP) and heart failure (HF) risk in the elderly remains incompletely defined, especially in individuals not receiving antihypertensive drugs. OBJECTIVE: To examine the association between SBP and HF risk in the elderly. DESIGN: Competing-risks proportional hazards modelling of incident HF risk, using 10-year follow-up data from two NIH-sponsored cohort studies: the Cardiovascular Health Study (inception: 1989-90 and 1992-3) and the Health ABC Study (inception: 1997-8). SETTING: Community-based cohorts. PARTICIPANTS: 4408 participants (age, 72.8 (4.9) years; 53.1% women, 81.7% white; 18.3% black) without prevalent HF and not receiving antihypertensive drugs at baseline. MAIN OUTCOME MEASURES: Incident HF, defined as first adjudicated hospitalisation for HF. RESULTS: Over 10 years, 493 (11.2%) participants developed HF. Prehypertension (120-139 mm Hg), stage 1 (140-159 mm Hg), and stage 2 (≥160 mm Hg) hypertension were associated with escalating HF risk; HRs versus optimal SBP (<120 mm Hg) in competing-risks models controlling for clinical characteristics were 1.63 (95% CI 1.23 to 2.16; p=0.001), 2.21 (95% CI 1.65 to 2.96; p<0.001) and 2.60 (95% CI 1.85 to 3.64; p<0.001), respectively. Overall 255/493 (51.7%) HF events occurred in participants with SBP <140 mm Hg at baseline. Increasing SBP was associated with higher HF risk in women than in men; no race-SBP interaction was seen. In analyses with continuous SBP, HF risk had a continuous positive association with SBP to levels as low as 113 mm Hg in men and 112 mm Hg in women. CONCLUSIONS: There is a continuous positive association between SBP and HF risk in the elderly for levels of SBP as low as <115 mm Hg; over half of incident HF events occur in individuals with SBP <140 mm Hg.
BACKGROUND: The exact form of the association between systolic blood pressure (SBP) and heart failure (HF) risk in the elderly remains incompletely defined, especially in individuals not receiving antihypertensive drugs. OBJECTIVE: To examine the association between SBP and HF risk in the elderly. DESIGN: Competing-risks proportional hazards modelling of incident HF risk, using 10-year follow-up data from two NIH-sponsored cohort studies: the Cardiovascular Health Study (inception: 1989-90 and 1992-3) and the Health ABC Study (inception: 1997-8). SETTING: Community-based cohorts. PARTICIPANTS: 4408 participants (age, 72.8 (4.9) years; 53.1% women, 81.7% white; 18.3% black) without prevalent HF and not receiving antihypertensive drugs at baseline. MAIN OUTCOME MEASURES: Incident HF, defined as first adjudicated hospitalisation for HF. RESULTS: Over 10 years, 493 (11.2%) participants developed HF. Prehypertension (120-139 mm Hg), stage 1 (140-159 mm Hg), and stage 2 (≥160 mm Hg) hypertension were associated with escalating HF risk; HRs versus optimal SBP (<120 mm Hg) in competing-risks models controlling for clinical characteristics were 1.63 (95% CI 1.23 to 2.16; p=0.001), 2.21 (95% CI 1.65 to 2.96; p<0.001) and 2.60 (95% CI 1.85 to 3.64; p<0.001), respectively. Overall 255/493 (51.7%) HF events occurred in participants with SBP <140 mm Hg at baseline. Increasing SBP was associated with higher HF risk in women than in men; no race-SBP interaction was seen. In analyses with continuous SBP, HF risk had a continuous positive association with SBP to levels as low as 113 mm Hg in men and 112 mm Hg in women. CONCLUSIONS: There is a continuous positive association between SBP and HF risk in the elderly for levels of SBP as low as <115 mm Hg; over half of incident HF events occur in individuals with SBP <140 mm Hg.
Authors: A B Newman; L Shemanski; T A Manolio; M Cushman; M Mittelmark; J F Polak; N R Powe; D Siscovick Journal: Arterioscler Thromb Vasc Biol Date: 1999-03 Impact factor: 8.311
Authors: Gina D Schellenbaum; Susan R Heckbert; Nicholas L Smith; Thomas D Rea; Thomas Lumley; Dalane W Kitzman; Veronique L Roger; Herman A Taylor; Bruce M Psaty Journal: Ann Epidemiol Date: 2005-06-16 Impact factor: 3.797
Authors: William C Cushman; Gregory W Evans; Robert P Byington; David C Goff; Richard H Grimm; Jeffrey A Cutler; Denise G Simons-Morton; Jan N Basile; Marshall A Corson; Jeffrey L Probstfield; Lois Katz; Kevin A Peterson; William T Friedewald; John B Buse; J Thomas Bigger; Hertzel C Gerstein; Faramarz Ismail-Beigi Journal: N Engl J Med Date: 2010-03-14 Impact factor: 91.245
Authors: Javed Butler; Andreas Kalogeropoulos; Vasiliki Georgiopoulou; Rhonda Belue; Nicolas Rodondi; Melissa Garcia; Douglas C Bauer; Suzanne Satterfield; Andrew L Smith; Viola Vaccarino; Anne B Newman; Tamara B Harris; Peter W F Wilson; Stephen B Kritchevsky Journal: Circ Heart Fail Date: 2008-07 Impact factor: 8.790
Authors: Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella Journal: Hypertension Date: 2003-12-01 Impact factor: 10.190
Authors: Kirsten Bibbins-Domingo; Feng Lin; Eric Vittinghoff; Elizabeth Barrett-Connor; Stephen B Hulley; Deborah Grady; Michael G Shlipak Journal: Circulation Date: 2004-09-07 Impact factor: 29.690
Authors: Harneet K Walia; Hong Li; Michael Rueschman; Deepak L Bhatt; Sanjay R Patel; Stuart F Quan; Daniel J Gottlieb; Naresh M Punjabi; Susan Redline; Reena Mehra Journal: J Clin Sleep Med Date: 2014-08-15 Impact factor: 4.062
Authors: Christopher C Smitson; Rebecca Scherzer; Michael G Shlipak; Bruce M Psaty; Anne B Newman; Mark J Sarnak; Michelle C Odden; Carmen A Peralta Journal: Am J Hypertens Date: 2017-06-01 Impact factor: 2.689
Authors: Harneet K Walia; Sandra D Griffith; Nancy Foldvary-Schaefer; George Thomas; Emmanuel L Bravo; Douglas E Moul; Reena Mehra Journal: Chest Date: 2016-01-08 Impact factor: 9.410